Ontario’s move to primary human papillomavirus (HPV) testing is changing cervical cancer screening and the laboratory practices that support it.
At the 2026 ASCP and Canadian Association of Pathologists (CAP-ACP) Joint Annual Scientific Meeting in Montréal, IQMH Cytopathology Scientific Committee members Dr. Carrie Robinson and Dr. Lananh Nguyen presented findings from an IQMH patterns-of-practice survey examining Ontario cytopathology laboratories before the implementation of primary HPV screening. The meeting took place November 17–20, 2026.
The survey provides an important baseline for understanding the impact of this transition. Of 46 hospital and community laboratories surveyed, 38 responded, an 82% response rate.
The findings point to a changing laboratory environment:
- Workforce capacity is under pressure. Laboratories reported a mean 25% decrease in cytotechnologist staffing compared with 2019.
- Workloads are shifting. While gynecologic cytology volumes were expected to change, 92% of laboratories expected non-gynecologic cytology volumes to remain unchanged or increase.
- Practices vary across Ontario. Differences were identified in turnaround times, specimen workflows, and HPV testing and reporting practices.
Together, these findings establish a benchmark for understanding how primary HPV screening may reshape laboratory workload, workforce needs and practices over time.
IQMH has since distributed a follow-up survey to examine the impact of primary HPV screening after implementation. Comparing the findings will help build a clearer picture of how laboratory practice is evolving and where new challenges and opportunities are emerging.
Thank you to the laboratories that contributed their experience and data to this work, and to the IQMH Cytopathology Scientific Committee for advancing this important conversation.